AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.

Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.

wallstreetcnJul 1 22:02 ET

Circuit Hyper | Future Intelligent Business Exploration: Individual AI Assistants Equal Rights

GAI's affirmative future commercial value thinking.

wallstreetcnMay 17 06:02 ET

AI concept stocks continue to differentiate in the third quarter report: Dawning Information Industry's net profit increases by 20% year-on-year, Kunlun Tech turns to loss, and Zhejiang Jinke Tom Culture Industry's net profit decreases significantly by 87

Dawning Information Industry has shown stable growth in the fields of information innovation and AI, Kunlun Tech has increased its overseas business income, and Zhejiang Jinke Tom Culture Industry's performance has declined due to global economic weakness and lack of new product launches.

wallstreetcnOct 26, 2023 09:56 ET

Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist

In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons

wallstreetcnSep 25, 2023 21:55 ET

China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Needed To Make A Generic Version Of Paxlovid

China's National Medical Products Administration In Late December Met With Several Chinese Drugmakers Including Zhejiang Huahai Pharmaceutical And CSPC Pharmaceutical Group To Discuss Preparations Nee

Benzinga Real-time NewsJan 6, 2023 11:32 ET

Lepu Biology officially landed on the Hong Kong Stock Exchange to focus on the field of tumor treatment.

02157.HK is officially listed on the Hong Kong Stock Exchange at HK $7.13 per share. Weiwu Capital (managed by Vivo Capital LLC), the cornerstone investor attracted by Lepu Biology's IPO, is the top fund in the global biomedical field. Another cornerstone investor, King Star, actually controls Lin Xianghong as a senior investor in the venture capital circle and has a wealth of successful investment experience in the industry. As cornerstone investors, Weiwu Capital and Lin Xianghong show that they are optimistic about the future development of Lepu Biology. It is understood that Lepu Biology on January 19, 2018

獨角獸早知道Feb 22, 2022 20:38 ET